Immunopeptidomic profiling of HLA-A2-positive triple negative breast cancer identifies potential immunotherapy target antigens

The recent development in immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cells in the treatment of cancer has not only demonstrated the potency of utilising T-cell reactivity for cancer therapy, but has also highlighted the need for developing new approaches to discover targets s...

Full description

Bibliographic Details
Main Authors: Ternette, N, Olde Nordkamp, M, Muller, J, Anderson, A, Nicastri, A, Hill, A, Kessler, B, Li, D
Format: Journal article
Language:English
Published: Wiley 2018
_version_ 1797078322949128192
author Ternette, N
Olde Nordkamp, M
Muller, J
Anderson, A
Nicastri, A
Hill, A
Kessler, B
Li, D
author_facet Ternette, N
Olde Nordkamp, M
Muller, J
Anderson, A
Nicastri, A
Hill, A
Kessler, B
Li, D
author_sort Ternette, N
collection OXFORD
description The recent development in immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cells in the treatment of cancer has not only demonstrated the potency of utilising T-cell reactivity for cancer therapy, but has also highlighted the need for developing new approaches to discover targets suitable for such novel therapeutics. Here we analysed the immunopeptidomes of 6 HLA-A2-positive triple negative breast cancer (TNBC) samples by nano-ultra performance liquid chromatography tandem mass spectrometry (nUPLC-MS2 ). Immunopeptidomic profiling identified a total of 19,675 peptides from tumour and adjacent normal tissue and 130 of the peptides were found to have higher abundance in tumour than in normal tissues. To determine potential therapeutic target proteins, we calculated the average tumour-associated cohort coverage (aTaCC) that represents the percentage coverage of each protein in this cohort by peptides that had higher tumourial abundance. Cofilin-1 (CFL-1), interleukin-32 (IL-32), proliferating cell nuclear antigen (PCNA), syntenin-1 (SDCBP) and ribophorin-2 (RPN-2) were found to have the highest aTaCC scores. We propose that these antigens could be evaluated further for their potential as targets in breast cancer immunotherapy and the small cohort immunopeptidomics analysis technique could be used in the wide spectrum of target discovery. This article is protected by copyright. All rights reserved.
first_indexed 2024-03-07T00:30:26Z
format Journal article
id oxford-uuid:7f986a73-f7c2-431d-a2a6-63084f58ce2c
institution University of Oxford
language English
last_indexed 2024-03-07T00:30:26Z
publishDate 2018
publisher Wiley
record_format dspace
spelling oxford-uuid:7f986a73-f7c2-431d-a2a6-63084f58ce2c2022-03-26T21:17:53ZImmunopeptidomic profiling of HLA-A2-positive triple negative breast cancer identifies potential immunotherapy target antigensJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:7f986a73-f7c2-431d-a2a6-63084f58ce2cEnglishSymplectic Elements at OxfordWiley2018Ternette, NOlde Nordkamp, MMuller, JAnderson, ANicastri, AHill, AKessler, BLi, DThe recent development in immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cells in the treatment of cancer has not only demonstrated the potency of utilising T-cell reactivity for cancer therapy, but has also highlighted the need for developing new approaches to discover targets suitable for such novel therapeutics. Here we analysed the immunopeptidomes of 6 HLA-A2-positive triple negative breast cancer (TNBC) samples by nano-ultra performance liquid chromatography tandem mass spectrometry (nUPLC-MS2 ). Immunopeptidomic profiling identified a total of 19,675 peptides from tumour and adjacent normal tissue and 130 of the peptides were found to have higher abundance in tumour than in normal tissues. To determine potential therapeutic target proteins, we calculated the average tumour-associated cohort coverage (aTaCC) that represents the percentage coverage of each protein in this cohort by peptides that had higher tumourial abundance. Cofilin-1 (CFL-1), interleukin-32 (IL-32), proliferating cell nuclear antigen (PCNA), syntenin-1 (SDCBP) and ribophorin-2 (RPN-2) were found to have the highest aTaCC scores. We propose that these antigens could be evaluated further for their potential as targets in breast cancer immunotherapy and the small cohort immunopeptidomics analysis technique could be used in the wide spectrum of target discovery. This article is protected by copyright. All rights reserved.
spellingShingle Ternette, N
Olde Nordkamp, M
Muller, J
Anderson, A
Nicastri, A
Hill, A
Kessler, B
Li, D
Immunopeptidomic profiling of HLA-A2-positive triple negative breast cancer identifies potential immunotherapy target antigens
title Immunopeptidomic profiling of HLA-A2-positive triple negative breast cancer identifies potential immunotherapy target antigens
title_full Immunopeptidomic profiling of HLA-A2-positive triple negative breast cancer identifies potential immunotherapy target antigens
title_fullStr Immunopeptidomic profiling of HLA-A2-positive triple negative breast cancer identifies potential immunotherapy target antigens
title_full_unstemmed Immunopeptidomic profiling of HLA-A2-positive triple negative breast cancer identifies potential immunotherapy target antigens
title_short Immunopeptidomic profiling of HLA-A2-positive triple negative breast cancer identifies potential immunotherapy target antigens
title_sort immunopeptidomic profiling of hla a2 positive triple negative breast cancer identifies potential immunotherapy target antigens
work_keys_str_mv AT ternetten immunopeptidomicprofilingofhlaa2positivetriplenegativebreastcanceridentifiespotentialimmunotherapytargetantigens
AT oldenordkampm immunopeptidomicprofilingofhlaa2positivetriplenegativebreastcanceridentifiespotentialimmunotherapytargetantigens
AT mullerj immunopeptidomicprofilingofhlaa2positivetriplenegativebreastcanceridentifiespotentialimmunotherapytargetantigens
AT andersona immunopeptidomicprofilingofhlaa2positivetriplenegativebreastcanceridentifiespotentialimmunotherapytargetantigens
AT nicastria immunopeptidomicprofilingofhlaa2positivetriplenegativebreastcanceridentifiespotentialimmunotherapytargetantigens
AT hilla immunopeptidomicprofilingofhlaa2positivetriplenegativebreastcanceridentifiespotentialimmunotherapytargetantigens
AT kesslerb immunopeptidomicprofilingofhlaa2positivetriplenegativebreastcanceridentifiespotentialimmunotherapytargetantigens
AT lid immunopeptidomicprofilingofhlaa2positivetriplenegativebreastcanceridentifiespotentialimmunotherapytargetantigens